HIV-1 RNA viral suppression is comparable between tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) regimens, according to updated results of the ADVANCE trial.
In the treatment of patients with type 2 diabetes mellitus, both glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-dependent glucose cotransporter-2 inhibitors (SGLT2-Is) help lower blood pressure, improve glucose control without inducing weight gain, and confer cardio- and renoprotection, as shown in a study.
A comprehensive meta-analysis of 13 prospective studies evaluating eight* fructose-containing foods revealed that not all fructose-containing sugar sources are adversely associated with metabolic syndrome (MetS).
Use of metformin leads to improved oncological outcomes in diabetic patients with nonmuscke invasive bladder cancer treated with intravesical Bacille Calmette-Guerin (BCG), according to a Singapore study.
A quantitative analysis of patient perspective during the first years after a successful weight reduction has identified four solid barriers to weight loss maintenance, namely mental distress, binge eating, hedonic hunger, and demoralization.
Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.
Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.